Royalty Pharma plc Class A Ordinary Shares

RPRXNASDAQ • USD
48.82 USD
↗ 0.39 (0.81%)AT CLOSE (11:59 AM EDT)
48.80
↗ 0.27 (0.56%)
POST MARKET (AS OF 06:46 PM EDT)
Post Market
AS OF 06:46 PM EDT
48.80
↗ 0.27 (0.56%)
🟢Market: OPEN
Open?$48.40
High?$49.01
Low?$48.35
Prev. Close?$48.43
Volume?3.9M
Avg. Volume?3.3M
VWAP?$48.77
Rel. Volume?1.18x
Bid / Ask
Bid?$46.23 × 100
Ask?$51.51 × 100
Spread?$5.28
Midpoint?$48.87
Valuation & Ratios
Market Cap?20.7B
Shares Out?428.4M
Float?406.4M
Float %?94.9%
P/E Ratio?26.91
P/B Ratio?3.20
EPS?$1.80
Dividend?3.53%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?2.40Strong
Quick Ratio?2.40Strong
Cash Ratio?0.97Adequate
Debt/Equity?1.40Moderate
ValuationRICHLY VALUED
Score
47/100
P/E?
26.9FAIR▾
P/B?
3.20FAIR▾
P/S?
8.72HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
20.2HIGH▾
EV/Sales?
12.27HIGH▾
Returns & Efficiency
ROE?
11.9%FAIR▾
ROA?
3.9%FAIR▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$29.2B
Related Companies
Loading...
News
Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Employees
100
Market Cap
20.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.royaltypharma.com
Listed
2020-06-16
Address
110 EAST 59TH STREET
NEW YORK, NY 10022
Phone: (212) 883-0200
MarketsMoversWatchlist